Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Type: Journal article
Title: Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Author: Apperley, J.
Cortes, J.
Kim, D.
Roy, L.
Roboz, G.
Rosti, G.
Bullorsky, E.
Abruzzese, E.
Hochhaus, A.
Heim, D.
De Souza, C.
Larson, R.
Lipton, J.
Khoury, J.
Kim, H.
Sillaber, C.
Hughes, T.
Erben, P.
Tornout, J.
Stone, R.
Citation: Journal of Clinical Oncology, 2009; 27(21):3472-3479
Publisher: Amer Soc Clinical Oncology
Issue Date: 2009
ISSN: 0732-183X
Statement of
Jane F. Apperley, Jorge E. Cortes, Dong-Wook Kim, Lydia Roy, Gail J. Roboz, Gianantonio Rosti, Eduardo O. Bullorsky, Elisabetta Abruzzese, Andreas Hochhaus, Dominik Heim, Carmino A. de Souza, Richard A. Larson, Jeffrey H. Lipton, H. Jean Khoury, Hyeoung-Joon Kim, Christian Sillaber, Timothy P. Hughes, Philipp Erben, Jan Van Tornout, Richard M. Stone
Abstract: PURPOSE Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant or intolerant to imatinib have limited therapeutic options. Dasatinib, a potent inhibitor of BCR-ABL and SRC-family kinases, has efficacy in patients with CML-AP who have experienced treatment failure with imatinib. We now report follow-up data from the full patient cohort of 174 patients enrolled onto a phase II trial to provide a more complete assessment of the efficacy and safety of dasatinib in this population. PATIENTS AND METHODS Patients with imatinib-resistant (n = 161) or -intolerant (n = 13) CML-AP received dasatinib 70 mg orally twice daily. Results At a median follow-up of 14.1 months (treatment duration, 0.1 to 21.7 months), major and complete hematologic responses were attained by 64% and 45% of patients, respectively, and major and complete cytogenetic responses were achieved in 39% and 32% of patients, respectively. Responses were achieved irrespective of imatinib status (resistant or intolerant), prior stem-cell transplantation, or the presence of prior BCR-ABL mutation. The 12-month progression-free survival and overall survival rates were 66% and 82%, respectively. Dasatinib was generally well tolerated; the most frequent nonhematologic severe treatment-related adverse event was diarrhea (52%; grade 3 to 4, 8%). Cytopenias were common, including grade 3 to 4 neutropenia (76%) and thrombocytopenia (82%). Pleural effusion occurred in 27% of patients (grade 3 to 4, 5%). CONCLUSION Dasatinib is effective in patients with CML-AP after imatinib treatment failure.
Keywords: Humans
Disease-Free Survival
Treatment Outcome
Treatment Failure
Aged, 80 and over
Middle Aged
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Young Adult
Imatinib Mesylate
DOI: 10.1200/JCO.2007.14.3339
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.